Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Dry Eye Disease (DED) Clinical Trial

Official title:

A Multicenter, Single-masked, Randomized Study to Compare the Efficacy and Safety of a New Artificial Tear Formulation (011516X) With Systane® Ultra Multidose for 90 Days in Participants With Dry Eye Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04393441
• Other study ID #: 2007-301-005
• Status: Completed
• Phase: Phase 3
• Start date: June 29, 2020
• Est. completion date: June 15, 2021

Study information

• Verified date: June 2022
• Source: Allergan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 400
• Est. completion date: June 15, 2021
• Est. primary completion date: June 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• At the Screening (Day -7) and Baseline (Day 1) visits, at least 1 eye must qualify based on corneal and conjunctival staining scores

• Have used an artificial tear product for DED within 6 months of the Screening (Day -7) visit

• Have ability/agreement to continue to wear existing current spectacle correction during the study period (if applicable)

• If using any form of topical ophthalmic cyclosporine (i.e., RESTASIS®) or lifitegrast 5% ophthalmic solution (Xiidra®), participants must be using the drops for =90 days prior to the Screening (Day -7) visit and plan to continue without change for the duration of the study

• A female participant is eligible to participate if she is not pregnant (i.e., has a negative in-office urine pregnancy test at Screening [Day -7] and does not verbally report pregnancy at the Day 1 [Baseline] visit; is not breastfeeding, and at least 1 of the following conditions applies:

1. A woman not of childbearing potential (WOCBP) OR

2. A WOCBP who agrees to follow the contraceptive guidance for the duration of the study

Exclusion Criteria:

• Have uncontrolled severe systemic disease that, in the assessment of the investigator, would put safety of the participant at risk through participation, or which would prevent or confound protocol-specified assessments (eg, hypertension and diabetes, Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, immunodeficiency disease, etc.)

• Participant has worn contact lenses in the last 90 days prior to the Screening (Day -7) visit and/or participant anticipates contact lens wear during the study

• Have any scheduled or planned systemic surgery or procedure during the study, which in the investigator's opinion, may impact the participant's study participation

• Presence of 1 or more of the following ocular conditions:

• Active ocular infection or non-keratoconjunctivitis sicca (KCS) ocular inflammation

• Active ocular allergy

• History of recurrent herpes keratitis or active disease within 6 months prior to the Screening (Day -7) visit

• Corneal disorder or abnormality that affects corneal sensitivity or normal spreading of the tear film (except superficial punctate keratitis)

• Severe blepharitis or obvious inflammation of the lid margin, which in the judgment of the investigator, may interfere with the interpretation of the study results

• Keratoconjunctivitis sicca secondary to the destruction of conjunctival goblet cells, such as occurs with vitamin A deficiency or scarring such as that with cicatricial pemphigoid, alkali burns, Stevens-Johnson syndrome, trachoma, or irradiation

• Substantial non-KCS keratitis with overlying corneal stain or other significant corneal findings not directly related to DED; in addition, participants with DED signs/symptoms (eg, filamentary keratitis) of a severity where topical monotherapy with an artificial tear would be inappropriate

• The start date of any systemic medication (including over-the-counter [OTC], herbal, prescription, or nutritional supplements) which may affect Dry Eye Disease (DED) or vision is <90 days prior to the Screening (Day -7) visit or a change in dosage is anticipated during the study.

Systemic medications, which may affect DED or vision, include but are not limited to the following: flax seed oil, fish oil, omega-3 supplements, cyclosporine, antihistamines, cholinergic agents, anticholinergics, antimuscarinics, beta blocking agents, tricyclic antidepressants, phenothiazines, estrogen, progesterone, and other estrogen derivatives

• Have occlusion of the lacrimal puncta for either eye, with punctal plugs or cauterization < 6 months prior to the Screening (Day -7) visit or anticipated use of such procedures during the study

• Use of lid-heating therapy (i.e., LipiFlow®, iLUX®, etc.), Meibomian gland probing, or therapeutic Meibomian gland expression in either eye < 6 months prior to the Screening visit (Day -7) or anticipated use during the study

• Have history of ocular/ophthalmic surgery or trauma, which could affect corneal sensitivity and/or tear distribution (eg, cataract surgery, laser-assisted in situ keratomileusis [LASIK], photorefractive keratectomy, or any surgery involving a limbal or corneal incision) within 12 months prior to the Screening (Day -7) visit

• Are currently using topical ocular medication (OTC, herbal or prescription) or TrueTear® (intranasal neurostimulator), or have used topical ocular medication (OTC, herbal or prescription) or TrueTear within 1 month of the Screening (Day -7) visit or plan use of such treatments during the study. Exception: participants who are using the following can be considered:

• Marketed artificial tear product for the management of DED, which must be discontinued at the Screening (Day -7) visit

• Monotherapy for glaucoma or ocular hypertension (OHT) using a prostaglandin analog, beta blocker, alpha-2 agonist, or carbonic anhydrase inhibitor; any topical intraocular pressure (IOP)-lowering medications must have a start date of = 90 days prior to the Screening (Day -7) visit and dosage is not expected to change during the study

• Cyclosporine topical ophthalmic preparation (eg, RESTASIS or other ophthalmic form) or lifitegrast 5% ophthalmic solution (Xiidra), with a start date of = 90 days prior to the Screening (Day -7) visit and dosage is not expected to change during the study NOTE: Participants currently being treated with BOTH an IOP-lowering medication and topical ocular cyclosporine or lifitegrast cannot be enrolled.

• Are currently enrolled in an investigational drug or device study or participation in such a study within 30 days of entry into this study at the Screening (Day -7) visit

• Report an average daily artificial tear use of >6 times per day within 6 months of the Screening (Day -7) visit

• Females who are pregnant, nursing, or planning a pregnancy during the study or females who are of childbearing potential and not using a reliable method of contraception

• Have history of allergies or sensitivity to the study interventions or its components (including all REFRESH and Systane product lines) or diagnostics (eg, topical ocular anesthetic, sodium fluorescein, or lissamine green).

Related Conditions & MeSH terms

• Dry Eye Disease (DED)
• Dry Eye Syndromes
• Eye Diseases
• Keratoconjunctivitis Sicca

Intervention

Drug:
• 011516X (New Artificial Tear Formulation)
Topical eye drops
• Systane Ultra Multidose
Topical eye drops
• REFRESH PLUS®
Topical eye drops

Locations

Country	Name	City	State
United States	Georgia Eye Partners	Atlanta	Georgia
United States	Milton M. Hom, OD, FAAO	Azusa	California
United States	Eye Care Associates of Greater Cincinnati, Inc. dba Apex Eye	Cincinnati	Ohio
United States	Nature Coast Clinical Research	Crystal River	Florida
United States	Global Research Management	Glendale	California
United States	Wake Forest Health Network Ophthalmology - Oak Hollow	High Point	North Carolina
United States	Bowden Eye & Associates	Jacksonville	Florida
United States	Moyes Eye Center	Kansas City	Missouri
United States	Senior Health Services	Louisville	Kentucky
United States	Total Eye Care, PA	Memphis	Tennessee
United States	South Florida Research Center, Inc.	Miami	Florida
United States	Vista Health Research, LLC	Miami	Florida
United States	DCT-Shah Research, LLC dba Discovery Clinical Trials	Mission	Texas
United States	Clayton Eye Clinical Research, LLC	Morrow	Georgia
United States	Advancing Vision Research	Nashville	Tennessee
United States	Eye Research Foundation	Newport Beach	California
United States	Alliance for Multispecialty Research, LLC	Newton	Kansas
United States	North Bay Eye Associates, Inc.	Petaluma	California
United States	Kannarr Eye Care, LLC	Pittsburg	Kansas
United States	Clinical Research Center of Florida	Pompano Beach	Florida
United States	Rochester Ophthalmological Group, PC	Rochester	New York
United States	Ophthalmology Associates	Saint Charles	Missouri
United States	Eric M. White OD Inc	San Diego	California
United States	Eye Care Associates of Nevada	Sparks	Nevada
United States	Wolstan & Goldberg Eye Associates	Torrance	California
United States	West Bay Eye Associates	Warwick	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy and safety of a new artificial tear formulation in participants with signs and symptoms of DED compared with Systane Ultra MD	The change from baseline in total staining score at Day 90.The total staining score will be the sum of corneal and conjunctival staining score using modified NEI grading scale.; The modified NEI/Industry Workshop guidelines will be used for grading the scale of corneal and conjunctival damage. The cornea is divided into five sectors and each of which is scored on a scale of 0-5, with a maximal total corneal staining score of 25. The conjunctiva is divided into six sectors and each of which is scored on a scale of 0-5, with a maximal total conjunctival staining score of 30.	90 Days
Secondary	Change from baseline in Current Symptom Survey (composite of all symptoms) at Day 90	A self-assessed 6-item visual analog scale (VAS) survey that assesses various symptoms of DED disease.; The participant's response to each item will be converted to a numerical value (0 to 100).	90 Days